Lida Bubuteishvili-Pacaud

TL;DR: Bvacizumab cannot be recommended as adjuvant treatment in unselected patients with triple-negative breast cancer and exploratory biomarker assessment suggests that patients with high pre-treatment plasma VEGFR-2 might benefit from the addition of bevaczumab.

TL;DR: There was no statistically significant improvement in IDFS with the addition of 1 year9s BEV to adjuvant CT for triple-negative BC, and the safety profile was consistent with previous reports in metastatic BC with a low incidence of fatal adverse events.

TL;DR: Unlike trials in metastatic BC (AVADO, AVEREL), in the adjuvant setting, baseline pVEGF-A concentration did not show predictive value for BEV efficacy with a median cut-off, however, analyses using the Q3 cut-offs suggest a trend toward predictive value.

TL;DR: In this paper , a single infusion of ciltacabtagene autoleucel (cilta-cel), a CAR-T cell therapy targeting BCMA, was shown to increase the median overall survival (OS) of patients with relapsed/refractory multiple myeloma.